Связь пропротеин конвертазы  субтилизин/кексин тип 9 (PCSK9)  с показателями липидного спектра  и глюкозой крови

K. S. Benimetskaya; M. P. Yachmeneva; M. O. Smolina; L. V. Shcherbakova; D. V. Denisova; Yu. I. Ragino; M. I. Voevoda

doi:10.34687/2219-8202.JAD.2019.03.0004

Authors

K. S. Benimetskaya Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Novosibirsk National Research State University
M. P. Yachmeneva Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science
M. O. Smolina Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science
L. V. Shcherbakova Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science
D. V. Denisova Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science
Yu. I. Ragino Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science
M. I. Voevoda Research Institute of Internal and Preventive Medicine – Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science

DOI:

https://doi.org/10.34687/2219-8202.JAD.2019.03.0004

Keywords:

proprotein convertase subtilisin/kexin type 9, PCSK9, hypercholesterolemia, glucose, population

Abstract

Objective: to estimate the level of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the population group of young men in Novosibirsk and the relationship of this protein with the lipid parameters and blood glucose.
Methods: the study included 492 men (25–45 years old) from the population sample of one of the typical districts of Novosibirsk, who underwent a one-time survey as part of the screening "Monitoring of health status and prevalence of risk factors of therapeutic diseases, their prediction and prevention in Siberia". Levels of PCSK9 was determined with ELISA, using a test system "Human PCSK9 ELISA" (BioVendor, Czech Republic).
Results: the average levels of PCSK9 amounted to 325.9 ± 141.97 ng/ml, median and interquartile range were 300.19 (240.20; 361.80), there was a high variability: the minimum level was 20.90 ng/ml, maximum – 1249.04 ng/ml. The distribution of PCSK9 differed from the normal and had a shift to the left. PCSK9 levels were higher in samples with total cholesterol (TC) ≥ 5 mmol/ l, low-density lipoprotein cholesterol (LDL-C) ≥ 3 mmol/ l, blood glucose ≥ 6.1 mmol/ l, blood glucose ≥ 5.6 mmol/l in estimating in pairs of independent samples differing in the level of TC, LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides (TG),
glucose, age, body mass index (BMI). A weak statistically significant correlation between PCSK9 and TC (r = 0.115 (p = 0.01)), LDL-C (r = 0.091 (p = 0.04)) and glucose levels (r = 0.1122; p = 0.007) was shown.
A multivariate regression analysis showed the association between PCSK9 and TC, glucose; blood glucose ≥ 6.1 was a significant predictor of PCSK9.
Conclusions: This study is the only one in Russia that gives an information about the levels of PCSK9 protein, the nature of its distribution, the relationship with lipid parameters and glucose in the population of young men and are of interest, since these indicators are population-specific. The level of PCSK9 in the male population of Novosibirsk was higher than in the majority of population studies. Found correlation with TC and LDL-C is compatible with those in the various world population-based studies. The identified relationships between PCSK9 protein and glucose are compatible with some studies and contribute to the study of the role of PCSK9 in metabolic homeostasis, which exact nature is to be determined.